H.R. 1843 has not moved since its introduction on Mar 5, 2025, with one cosponsor, a Democrat
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
IntroducedMar 5, 2025
Reported—
Passed one chamber—
Passed both—
Law—
What it changes · CRS summary
Written by the Congressional Research Service [2]. 53 words.
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
Context
- Committees
- House Energy and Commerce Committee
- Policy area
- Health: 122 of 9,357 bills became law, 113th–118th (1.3%)
- Sponsor
- 1 of 86 bills enacted since 2013
- Text versions
- 1: introduced in house · 591 words
- Latest action
- Mar 5, 2025: Referred to the House Committee on Energy and Commerce.
- Records
- Congress.gov · Bill text
Exhibit 1Passage odds band at each stage, rated when the bill reached it [4]
Related bills · 4
Each bill appears once, under its strongest link. 4 in all.
Related, per CRS or House · 4
- 119th H.R. 1768 Lower Costs for Everyday Americans Act D · Introduced
- 119th H.R. 7148 Consolidated Appropriations Act, 2026 R · Law
- 119th S. 1302 Increasing Transparency in Generic Drug Applications Act D · Introduced
- 119th S. 891 Bipartisan Health Care Act D · Introduced
Exhibit 2Articles naming the bill per day, last 90 days, US sources [3]